{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:31:12Z","timestamp":1768015872308,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.mr000051","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000}}],"reference-count":131,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.mr000051.pub2","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T12:07:06Z","timestamp":1638965226000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Monitoring strategies for clinical intervention studies"],"prefix":"10.1002","volume":"2022","author":[{"given":"Katharina","family":"Klatte","sequence":"additional","affiliation":[{"name":"Department of Clinical Research; University Hospital Basel and University of Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Pauli-Magnus","sequence":"additional","affiliation":[{"name":"Department of Clinical Research; University Hospital Basel and University of Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon B","family":"Love","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL; University College London; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R","family":"Sydes","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL; University College London; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Benkert","sequence":"additional","affiliation":[{"name":"Department of Clinical Research; University Hospital Basel and University of Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Bruni","sequence":"additional","affiliation":[{"name":"Department of Clinical Research; University Hospital Basel and University of Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Ewald","sequence":"additional","affiliation":[{"name":"University Medical Library; University of Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Arnaiz Jimenez","sequence":"additional","affiliation":[{"name":"Department of Clinical Research; University Hospital Basel and University of Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Mi","family":"Bonde","sequence":"additional","affiliation":[{"name":"Department of Clinical Research; University Hospital Basel and University of Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Briel","sequence":"additional","affiliation":[{"name":"Department of Clinical Research; University Hospital Basel and University of Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"10.1002\/14651858.MR000051.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/1740774509347398","article-title":"Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials","volume":"6","author":"Brosteanu","year":"2009","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/1740774517724165","article-title":"Risk-adapted monitoring is not inferior to extensive on-site monitoring: results of the ADAMON cluster-randomised study","volume":"14","author":"Brosteanu","year":"2017","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0003|cit3","unstructured":"Study protocol (\"Prospektive cluster-randomisierte Untersuchung studienspezifisch adaptierterStrategien f\u00fcr das Monitoring vor Ort in Kombination mit zus\u00e4tzlichenqualit\u00e4tssichernden Ma\u00dfnahmen\") www.tmf-ev.de\/ADAMON\/Downloads.aspx"},{"issue":"S1","key":"10.1002\/14651858.MR000051.pub2-BIB0004|cit4","first-page":"49 (PM2","article-title":"Cost-effectiveness of full versus targeted monitoring of randomized controlled trials","volume":"32","author":"Fougerou-Leurent","year":"2018","journal-title":"Fundamental & Clinical Pharmacology"},{"issue":"12","key":"10.1002\/14651858.MR000051.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1111\/bcp.14108","article-title":"Impact of a targeted monitoring on data-quality and data-management workload of randomized controlled trials: a prospective comparative study","volume":"85","author":"Fougerou-Leurent","year":"2019","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1740774513480003","article-title":"Remote preenrollment checking of consent forms to reduce nonconformity","volume":"10","author":"Journot","year":"2013","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cct.2010.10.001","article-title":"Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies - the Pre-Optimon study","volume":"32","author":"Journot","year":"2011","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0008|cit8","unstructured":"Journot V OPTIMON - first results of the French trial on optimisation of monitoring ssl2.isped.u-bordeaux2.fr\/OPTIMON\/docs\/Communications\/2015-Montpellier\/OPTIMON%20-%20EpiClin%20Montpellier%202015-05-20%20EN.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0009|cit9","unstructured":"Journot V OPTIMON - the French trial on optimization of monitoring SCT Annual Meeting; 2017 May 7-10; Liverpool, UK"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0010|cit10","unstructured":"Study protocol: evaluation of the efficacy and cost of two monitoring strategies for public clinical research. OPTIMON study: OPTImisation of MONitoring ssl2.isped.u-bordeaux2.fr\/OPTIMON\/DOCS\/OPTIMON%20-%20Protocol%20v12.0%20EN%202008-04-21.pdf"},{"issue":"Suppl 2","key":"10.1002\/14651858.MR000051.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"O49","DOI":"10.1186\/1745-6215-16-S2-O49","article-title":"Improving efficiency of on-site monitoring in multicentre clinical trials by targeting visits","volume":"16","author":"Knott","year":"2015","journal-title":"Trials"},{"issue":"5","key":"10.1002\/14651858.MR000051.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1177\/1740774506070807","article-title":"Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer","volume":"3","author":"Li\u00e9nard","year":"2006","journal-title":"Clinical Trials"},{"issue":"12","key":"10.1002\/14651858.MR000051.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"e81890","DOI":"10.1371\/journal.pone.0081890","article-title":"Remote source document verification in two national clinical trials networks: a pilot study","volume":"8","author":"Mealer","year":"2013","journal-title":"PloS One"},{"issue":"1","key":"10.1002\/14651858.MR000051.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/1740774520972650","article-title":"Assessing the potential for prevention or earlier detection of on-site monitoring findings from randomised controlled trials: further analyses of findings from the prospective TEMPER triggered monitoring study","volume":"18","author":"Cragg","year":"2021","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0015|cit15","first-page":"P149","article-title":"Managing our TEMPER: monitoring triggers and site matching algorithms for defining triggered and control sites in the temper study","volume":"18","author":"Diaz-Montana","year":"2017","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13063-019-3301-z","article-title":"Implementing monitoring triggers and matching of triggered and control sites in the TEMPER study: a description and evaluation of a triggered monitoring management system","volume":"20","author":"Diaz-Montana","year":"2019","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/1740774518793379","article-title":"Triggered or routine site monitoring visits for randomised controlled trials: results of TEMPER, a prospective, matched-pair study","volume":"15","author":"Stenning","year":"2018","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0018|cit18","unstructured":"Study protocol: TEMPER (TargetEd Monitoring: Prospective Evaluation and Refinement) prospective evaluation and refinement of a targeted on-site monitoring strategy for multicentre cancer clinical trials journals.sagepub.com\/doi\/suppl\/10.1177\/1740774518793379\/suppl_file\/793379_supp_mat_2.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/2168479014555912","article-title":"Investigating the efficacy of clinical trial monitoring strategies: design and implementation of the cluster randomized START monitoring substudy","volume":"49","author":"Hullsiek","year":"2015","journal-title":"Therapeutic Innovation and Regulatory Science"},{"issue":"1","key":"10.1002\/14651858.MR000051.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1740774519881616","article-title":"A randomized evaluation of on-site monitoring nested in a multinational randomized trial","volume":"17","author":"Wyman Engen","year":"2020","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.clinthera.2018.04.020","article-title":"Risk-based monitoring of clinical trials: an integrative approach","volume":"40","author":"Agrafiotis","year":"2018","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bcp.12531","article-title":"Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials","volume":"79","author":"Andersen","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0023|cit23","first-page":"220","article-title":"Implementing a risk based monitoring approach in the early phase myeloma portfolio at Leeds CTRU","volume":"18","author":"Bailey","year":"2017","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0024|cit24","first-page":"454","article-title":"The potential for central monitoring techniques to replace on-site monitoring in clinical trials: a review of monitoring findings from an international multi-centre clinical trial","volume":"8","author":"Bakobaki","year":"2011","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1740774511427325","article-title":"The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial","volume":"9","author":"Bakobaki","year":"2012","journal-title":"Clinical Trials"},{"issue":"9","key":"10.1002\/14651858.MR000051.pub2-BIB0026|cit26","first-page":"E10","article-title":"Implementing risk-based monitoring (RBM) in STEADY-PD III, a phase III multi-site clinical drug trial for Parkinson disease","volume":"31","author":"Biglan","year":"2016","journal-title":"Movement Disorders"},{"issue":"Suppl 1","key":"10.1002\/14651858.MR000051.pub2-BIB0027|cit27","first-page":"P","article-title":"Automation of clinical trial statistical monitoring","volume":"20","author":"Collett","year":"2019","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13063-019-3343-2","article-title":"Early warnings and repayment plans: novel trial management methods for monitoring and managing data return rates in a multi-centre phase III randomised controlled trial with paper case report forms","volume":"20","author":"Cragg","year":"2019","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0029|cit29","first-page":"25","article-title":"Monitoring strategies for clinical trials in primary care: an independent clinical research perspective","volume":"123","author":"Del Alamo","year":"2018","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/1740774517723589","article-title":"An evaluation of the effectiveness of a risk-based monitoring approach implemented with clinical trials involving implantable cardiac medical devices","volume":"14","author":"Diani","year":"2017","journal-title":"Clinical Trials"},{"issue":"Suppl 1","key":"10.1002\/14651858.MR000051.pub2-BIB0031|cit31","first-page":"P","article-title":"Making performance metrics work: developing a triggered monitoring management system","volume":"20","author":"Diaz-Montana","year":"2019","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/1740774513514145","article-title":"Central and statistical data monitoring in the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial","volume":"11","author":"Edwards","year":"2014","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"A135","DOI":"10.1186\/1745-6215-12-S1-A135","article-title":"A key risk indicator approach to central statistical monitoring in multicentre clinical trials: method development in the context of an ongoing large-scale randomized trial","volume":"12","author":"Elsa","year":"2011","journal-title":"Trials"},{"issue":"3","key":"10.1002\/14651858.MR000051.pub2-BIB0034|cit34","first-page":"209","article-title":"A preliminary analysis of remote monitoring practice in clinical trials","volume":"30","author":"Fu","year":"2021","journal-title":"Chinese Journal of New Drugs"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"100566","DOI":"10.1016\/j.conctc.2020.100566","article-title":"Bayesian central statistical monitoring using finite mixture models in multicenter clinical trials","volume":"19","author":"Hatayama","year":"2020","journal-title":"Contemporary Clinical Trials Communication"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0036|cit36","first-page":"A6041","article-title":"Central statistical monitoring of an international thromboprophylaxis trial","volume":"181","author":"Heels-Ansdell","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.MR000051.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s43441-019-00037-x","article-title":"Risk-based monitoring approach to ensure the quality of clinical study data and enable effective monitoring","volume":"54","author":"Higa","year":"2020","journal-title":"Therapeutic Innovation and Regulatory Science"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0038|cit38","first-page":"s150","article-title":"Development of an efficient monitoring method for investigator-initiated clinical trials: lessons from the experience of ATACH-II trial","volume":"44","author":"Hirase","year":"2016","journal-title":"Japanese Pharmacology and Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.MR000051.pub2-BIB0039|cit39","first-page":"P","article-title":"On-site monitoring of primary outcomes is important in primary care clinical trials: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK-D) trial - a case study","volume":"20","author":"Jones","year":"2019","journal-title":"Trials"},{"issue":"Suppl 3","key":"10.1002\/14651858.MR000051.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"gfaa143.P1734","DOI":"10.1093\/ndt\/gfaa143.P1734","article-title":"Information and communication technology-based centralized monitoring system to increase adherence to immunosuppressive medication in kidney transplant recipients: a randomized controlled trial","volume":"35","author":"Jung","year":"2020","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0041|cit41","first-page":"450","article-title":"Integration of site performance monitoring module in web-based CTMS for a global trial","volume":"8","author":"Kim","year":"2011","journal-title":"Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.MR000051.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s43441-020-00204-5","article-title":"Feasibility of a hybrid risk-adapted monitoring system in investigator-sponsored trials in cancer","volume":"55","author":"Kim","year":"2021","journal-title":"Therapeutic Innovation and Regulatory Science"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jclinepi.2010.10.003","article-title":"A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance","volume":"64","author":"Lane","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0044|cit44","first-page":"404","article-title":"Improving trial quality through a new site monitoring process: experience from the Protect Study","volume":"5","author":"Lane","year":"2008","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1745-6215-14-S1-O80","article-title":"Evaluation of source data verification in a multicentre cancer trial (PROTECT)","volume":"14","author":"Lane","year":"2013","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"ATP371","DOI":"10.1161\/str.48.suppl_1.tp371","article-title":"Monitoring a large-scale international cluster stroke trial: lessons from head position in stroke trial","volume":"48","author":"Lim","year":"2017","journal-title":"Stroke"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0047|cit47","first-page":"303","article-title":"Cost effective central monitoring of clinical trials","volume":"45","author":"Lindley","year":"2015","journal-title":"Neuroepidemiology"},{"issue":"8","key":"10.1002\/14651858.MR000051.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jjco\/hyz050","article-title":"Study risk assessment of Japan Clinical Oncology Group (JCOG) clinical trials using the European Organisation for Research and Treatment of Cancer (EORTC) study risk calculator","volume":"49","author":"Miyamoto","year":"2019","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1016\/j.joca.2020.02.721","article-title":"Case studies on the use of central statistical monitoring and interventions to optimize data quality in clinical trials","volume":"28","author":"Morales","year":"2020","journal-title":"Osteoarthritis and Cartilage"},{"issue":"Suppl 1","key":"10.1002\/14651858.MR000051.pub2-BIB0050|cit50","first-page":"P","article-title":"An assessment of feasibility and cost-effectiveness of remote monitoring on a multicentre observational study","volume":"20","author":"Murphy","year":"2019","journal-title":"Trials"},{"issue":"17","key":"10.1002\/14651858.MR000051.pub2-BIB0051|cit51","first-page":"2113","article-title":"Enhancing the system of expedited reporting of safety data during clinical trials of drugs and strengthening the management of clinical trial risk monitoring","volume":"28","author":"Pei","year":"2019","journal-title":"Chinese Journal of New Drugs"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0052|cit52","first-page":"200","article-title":"Surveillance of clinical trial performance using centralized statistical monitoring","volume":"18","author":"Stock","year":"2017","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/2168479017705155","article-title":"Investigation of the factors affecting risk-based quality management of investigator-initiated investigational new-drug trials for unapproved anticancer drugs in Japan","volume":"51","author":"Sudo","year":"2017","journal-title":"Therapeutic Innovation and Regulatory Science"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"58S","DOI":"10.1016\/0197-2456(96)84566-1","article-title":"Clinical trial monitoring in the face of changing clinical practice. The NICHD MFMU Network","volume":"17","author":"Thom","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"12","key":"10.1002\/14651858.MR000051.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"e51623","DOI":"10.1371\/journal.pone.0051623","article-title":"The value of source data verification in a cancer clinical trial","volume":"7","author":"Tudur Smith","year":"2012","journal-title":"PloS One"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12874-017-0308-6","article-title":"Generating evidence on a risk-based monitoring approach in the academic setting - lessons learned","volume":"17","author":"Niederh\u00e4usern","year":"2017","journal-title":"BMC Medical Research Methodology"},{"issue":"2","key":"10.1002\/14651858.MR000051.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1740774520971254","article-title":"Clinical trial monitoring effectiveness: remote risk-based monitoring versus on-site monitoring with 100% source data verification","volume":"18","author":"Yamada","year":"2021","journal-title":"Clinical Trials (London, England)"},{"issue":"Suppl 1","key":"10.1002\/14651858.MR000051.pub2-BIB0058|cit58","first-page":"P","article-title":"Risk-based trial monitoring: site performance metrics across time","volume":"20","author":"Yorke-Edwards","year":"2019","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0059|cit59","first-page":"S4","article-title":"Risk-based monitoring approach in practice-combination of real-time central monitoring and on-site source document verification","volume":"10","author":"Zhao","year":"2013","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0060|cit60","unstructured":"ADAMON study protocol Study protocol (\"Prospektive cluster-randomisierte Untersuchung studienspezifisch adaptierterStrategien f\u00fcr das Monitoring vor Ort in Kombination mit zus\u00e4tzlichenqualit\u00e4tssichernden Ma\u00dfnahmen\") www.tmf-ev.de\/ADAMON\/Downloads.aspx"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1756-5391.2012.01169.x","article-title":"Education section: Studies Within A Trial (SWAT)","volume":"5","year":"2012","journal-title":"Journal of Evidence-based Medicine"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1740774507087554","article-title":"Ensuring trial validity by data quality assurance and diversification of monitoring methods","volume":"5","author":"Baigent","year":"2008","journal-title":"Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.MR000051.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/jebm.12375","article-title":"A telephone reminder to enhance adherence to interventions in cardiovascular randomized trials: a protocol for a Study Within A Trial (SWAT)","volume":"13","author":"Bensaaud","year":"2020","journal-title":"Journal of Evidence-based Medicine"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/1740774509347398","article-title":"Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials","volume":"6","author":"Brosteanu","year":"2009","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/1740774517724165","article-title":"Risk-adapted monitoring is not inferior to extensive on-site monitoring: results of the ADAMON cluster-randomised study","volume":"14","author":"Brosteanu","year":"2017","journal-title":"Clinical Trials"},{"issue":"7","key":"10.1002\/14651858.MR000051.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s10147-020-01726-6","article-title":"Central statistical monitoring of investigator-led clinical trials in oncology","volume":"25","author":"Buyse","year":"2020","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0067|cit67","unstructured":"Chene G Evaluation of the efficacy and cost of two monitoring strategies for public clinical research. OPTIMON study: OPTImisation of MONitoring ssl2.isped.u-bordeaux2.fr\/OPTIMON\/DOCS\/OPTIMON%20-%20Protocol%20v12.0%20EN%202008-04-21.pdf"},{"issue":"1","key":"10.1002\/14651858.MR000051.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/1740774520972650","article-title":"Assessing the potential for prevention or earlier detection of on-site monitoring findings from randomised controlled trials: further analyses of findings from the prospective TEMPER triggered monitoring study","volume":"18","author":"Cragg","year":"2021","journal-title":"Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.MR000051.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1740774520976561","article-title":"Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: a scoping review","volume":"18","author":"Cragg","year":"2021","journal-title":"Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.MR000051.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13063-019-3301-z","article-title":"Implementing monitoring triggers and matching of triggered and control sites in the TEMPER study: a description and evaluation of a triggered monitoring management system","volume":"20","author":"Diaz-Montana","year":"2019","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1740774507087704","article-title":"Specific barriers to the conduct of randomised trials","volume":"5","author":"Duley","year":"2008","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0073|cit73","unstructured":"European Commission Risk proportionate approaches in clinical trials. Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No 536\/2014 on clinical trials on medicinal products for human use ec.europa.eu\/health\/sites\/default\/files\/files\/eudralex\/vol-10\/2017_04_25_risk_proportionate_approaches_in_ct.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0074|cit74","unstructured":"European Medicines Agency Reflection paper on risk based quality management in clinical trials, 2013 ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guidelines\/2013\/11\/WC500155491.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0075|cit75","unstructured":"European Medicines Agency Procedure for reporting of GCP inspections requested by the Committee for Medicinal Products for Human Use, 2017 ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ins-gcp-4-procedure-reporting-good-clinical-practice-inspections-requested-chmp_en.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0076|cit76","unstructured":"EMA European Medicines Agency Guidance on the management of clinical trial during the COVID-19 (coronavirus) pandemic European Medicines Agency 2021 V4 https:\/\/ec.europa.eu\/health\/sites\/default\/files\/files\/eudralex\/vol-10\/guidanceclinicaltrials_covid19_en.pdf (accessed August 2021)"},{"issue":"5","key":"10.1002\/14651858.MR000051.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1740774519862528","article-title":"Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application","volume":"16","author":"Embleton-Thirsk","year":"2019","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0078|cit78","unstructured":"What study designs should be included in an EPOC review and what should they be called? EPOC resources for review authors, 2016 epoc.cochrane.org\/sites\/epoc.cochrane.org\/files\/public\/uploads\/EPOC%20Study%20Designs%20About.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0079|cit79","unstructured":"Suggested risk of bias criteria for EPOC reviews. EPOC resources for review authors, 2017 epoc.cochrane.org\/sites\/epoc.cochrane.org\/files\/public\/uploads\/Resources-for-authors2017\/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0080|cit80","unstructured":"US Department of Health and Human Services Food and Drug Administration Guidance for industry oversight of clinical investigations - a risk-based approach to monitoring www.fda.gov\/downloads\/Drugs\/Guidances\/UCM269919.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0081|cit81","unstructured":"FDA guidance on conduct of clinical trials of medical products during COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards, 2020 www.fda.gov\/media\/136238\/download"},{"issue":"1","key":"10.1002\/14651858.MR000051.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/qaj.433","article-title":"Quality assurance within the scope of good clinical practice (GCP) - what is the cost of GCP-related activities? A survey within the Swedish Association of the Pharmaceutical Industry (LIF)'s members","volume":"12","author":"Funning","year":"2009","journal-title":"Quality Assurance Journal"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41569-020-00439-7","article-title":"The COVID-19 pandemic: a catalyst to improve clinical trials","volume":"17","author":"Gaba P Bhatt","year":"2020","journal-title":"Nature Reviews. Cardiology"},{"issue":"1","key":"10.1002\/14651858.MR000051.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/2168479015618696","article-title":"Defining a central monitoring capability: sharing the experience of TransCelerateBioPharmas approach, part 2","volume":"50","author":"Gough","year":"2016","journal-title":"Therapeutic Innovation and Regulatory Science"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0085|cit85","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime Inc) 2020"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4415\/ANN_11_01_04","article-title":"The Clinical Trials Transformation Initiative (CTTI)","volume":"47","author":"Grignolo","year":"2011","journal-title":"Annali dell'Istituto Superiore di Sanita"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles - continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2006.09.016","article-title":"The impact of the 'Clinical Trials' directive on the cost and conduct of non-commercial cancer trials in the UK","volume":"43","author":"Hearn","year":"2007","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0090|cit90","volume-title":"Methodological Expectations of Cochrane Intervention Reviews","author":"Higgins","year":"2016"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0091|cit91","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from handbook: training.cochrane.org\/handbook\/archive\/v6.1"},{"issue":"8","key":"10.1002\/14651858.MR000051.pub2-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000026.pub2","article-title":"Checking reference lists to find additional studies for systematic reviews","author":"Horsley","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.MR000051.pub2-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000045.pub2","article-title":"Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis","author":"Houghton","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.MR000051.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/2168479014555912","article-title":"Investigating the efficacy of clinical trial monitoring strategies: design and implementation of the cluster randomized START monitoring substudy","volume":"49","author":"Hullsiek","year":"2015","journal-title":"Therapeutic Innovation and Regulatory Science"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cct.2016.09.003","article-title":"Risk based monitoring (RBM) tools for clinical trials: a systematic review","volume":"51","author":"Hurley","year":"2016","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0096|cit96","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline: guideline for good clinical practice E6 (R2) www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0097|cit97","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Integrated Addendum to ICH E6(R1): guideline for good clinical practice E6R(2) database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf"},{"issue":"5","key":"10.1002\/14651858.MR000051.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/cts.12834","article-title":"Remote monitoring in clinical trials during the COVID-19 pandemic","volume":"13","author":"Izmailova","year":"2020","journal-title":"Clinical and Translational Science"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cct.2010.10.001","article-title":"Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies - the Pre-Optimon study","volume":"32","author":"Journot","year":"2011","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1740774513480003","article-title":"Remote preenrollment checking of consent forms to reduce nonconformity","volume":"10","author":"Journot","year":"2013","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0101|cit101","unstructured":"Journot V OPTIMON - first results of the French trial on optimisation of monitoring ssl2.isped.u-bordeaux2.fr\/OPTIMON\/docs\/Communications\/2015-Montpellier\/OPTIMON%20-%20EpiClin%20Montpellier%202015-05-20%20EN.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1177\/0092861512464372","article-title":"Clinical trials: rethinking how we ensure quality","volume":"46","author":"Landray","year":"2012","journal-title":"Drug Information Journal"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0103|cit103","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13063-021-05225-5","article-title":"Monitoring advances including consent: learning from COVID-19 trials and other trials running in UKCRC registered clinical trials units during the pandemic","volume":"22","author":"Love","year":"2021","journal-title":"Trials"},{"issue":"21","key":"10.1002\/14651858.MR000051.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1001\/jama.2020.4689","article-title":"Preserving clinical trial integrity during the coronavirus pandemic","volume":"323","author":"McDermott","year":"2020","journal-title":"JAMA"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"A39","DOI":"10.1186\/1745-6215-12-S1-A39","article-title":"Risk-adapted approaches to the management of clinical trials: guidance from the Department of Health (DH) \/ Medical Research Council (MRC)\/Medicines and Healthcare Products Regulatory Agency (MHRA) Clinical Trials Working Group","volume":"12","author":"Meredith","year":"2011","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.MR000051.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/1740774511402703","article-title":"Monitoring the quality of conduct of clinical trials: a survey of current practices","volume":"8","author":"Morrison","year":"2011","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0110|cit110","unstructured":"Organisation for Economic Co-operation and Development OECD recommendation on the governance of clinical trials oecd.org\/sti\/inno\/oecdrecommendationonthegovernanceofclinicaltrials.htm"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00228-015-2004-y","article-title":"The impact of clinical trial monitoring approaches on data integrity and cost? A review of current literature","volume":"72","author":"Olsen","year":"2016","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0112|cit112","unstructured":"OPTIMON study protocol Study protocol: evaluation of the efficacy and cost of two monitoring strategies for public clinical research. OPTIMON study: OPTImisation of MONitoring ssl2.isped.u-bordeaux2.fr\/OPTIMON\/DOCS\/OPTIMON%20-%20Protocol%20v12.0%20EN%202008-04-21.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-116-1-78","article-title":"A consumer's guide to subgroup analyses","volume":"116","author":"Oxman","year":"1992","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0114|cit114","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0115|cit115","unstructured":"Monitoring Platform of the Swiss Clinical Trial Organisation (SCTO) F dated Fact sheet: central data monitoring in clinical trials? V 1.0 www.scto.ch\/monitoring"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13063-020-05004-8","article-title":"Managing clinical trials during COVID-19: experience from a clinical research facility","volume":"22","author":"Shiely","year":"2021","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/1740774518793379","article-title":"Triggered or routine site monitoring visits for randomised controlled trials: results of TEMPER, a prospective, matched-pair study","volume":"15","author":"Stenning","year":"2018","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"c117","DOI":"10.1136\/bmj.c117","article-title":"Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses","volume":"340","author":"Sun","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/2168479015586001","article-title":"Risk-based monitoring: a closer statistical look at source document verification, queries, study size effects, and data quality","volume":"49","author":"Tantsyura","year":"2015","journal-title":"Therapeutic Innovation and Regulatory Science"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0120|cit120","unstructured":"EPPI-Reviewer: software for research synthesis. EPPI-Centre Software Thomas J Brunton J Graziosi S Social Science Research Unit, Institute of Education, University of London 2010"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0121|cit121","unstructured":"Risk-based monitoring methodology www.transceleratebiopharmainc.com\/wp-content\/uploads\/2016\/01\/TransCelerate-RBM-Position-Paper-FINAL-30MAY2013.pdf"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13063-018-2535-5","article-title":"Trial Forge Guidance 1: what is a Study Within A Trial (SWAT)?","volume":"19","author":"Treweek","year":"2018","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.MR000051.pub2-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000013.pub6","article-title":"Strategies to improve recruitment to randomised trials","author":"Treweek","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"e51623","DOI":"10.1371\/journal.pone.0051623","article-title":"The value of source data verification in a cancer clinical trial","volume":"7","author":"Tudur Smith","year":"2012","journal-title":"PloS One"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1745-6215-15-127","article-title":"Risk-proportionate clinical trial monitoring: an example approach from a non-commercial trials unit","volume":"15","author":"Tudur Smith","year":"2014","journal-title":"Trials"},{"issue":"Suppl 1","key":"10.1002\/14651858.MR000051.pub2-BIB0126|cit126","first-page":"A135","article-title":"A key risk indicator approach to central statistical monitoring in multicentre clinical trials: method development in the context of an ongoing large-scale randomized trial","volume":"12","author":"Vald\u00e9s-M\u00e1rquez","year":"2011","journal-title":"Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1740774512447898","article-title":"A statistical approach to central monitoring of data quality in clinical trials","volume":"9","author":"Venet","year":"2012","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.MR000051.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12874-017-0308-6","article-title":"Generating evidence on a risk-based monitoring approach in the academic setting - lessons learned","volume":"17","author":"Niederhausern","year":"2017","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.MR000051.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1740774519881616","article-title":"A randomized evaluation of on-site monitoring nested in a multinational randomized trial","volume":"17","author":"Wyman Engen","year":"2020","journal-title":"Clinical Trials"},{"issue":"11","key":"10.1002\/14651858.MR000051.pub2-BIB0130|cit130","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000027.pub2","article-title":"Methods for obtaining unpublished data","author":"Young","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.MR000051.pub2-BIB0131|cit131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000051","article-title":"Monitoring strategies for clinical intervention studies","author":"Klatte","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T18:10:14Z","timestamp":1699985414000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.MR000051.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Methodology Review Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.mr000051.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]}}}